Sonder Capital
VC Fund
Redwood City, United States
Sonder Capital is a VC fund in Redwood City focused on Health Care and Medical Device. Sonder Capital invests in teams and technologies that can transform healthcare in the medical device, diagnostic and healthtech sectors. We are Foundational Investors – we commit our energy and capital early to guide and support companies from inception to acquisition or IPO. We look for big ideas that will change lives.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Sonder Capital invests in
Stages Sonder Capital invests in
Countries Sonder Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $8M–$18M
- Series A
- $13M–$22M
- Series B
- $20M–$70M
Investment Focus
Industry
- Health Care 7 (30%)
- Medical Device 5 (22%)
- Medical 3 (13%)
- Biotechnology 2 (9%)
- Manufacturing 2 (9%)
Stage
- Series A 5 (22%)
- Seed 2 (9%)
- Series B 1 (4%)
- Series C 1 (4%)
Country
- United States 5 (22%)
- France 1 (4%)
- United Kingdom 1 (4%)
- The Netherlands 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andy McGibbon
Managing Partner
|
Managing Partner | Total investments: 4 | Find email | |
Jay Watkins
Managing Partner
|
Managing Partner | Total investments: 13 | Find email | |
Colby Wood
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
Fred Moll, M.D
Managing Partner
|
Managing Partner | Total investments: 28 | Find email | |
Kate Garrett
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SquareMind
|
Come build the future of healthcare with us. | $18M / Seed / Apr 28, 2026 | |
|
SquareMind
|
Come build the future of healthcare with us. | $18M / Seed / Apr 28, 2026 | |
Vitestro
|
Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | |
|
Vitestro
|
Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | |
Cordance Medical
|
Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases. | $8M / Seed / Nov 24, 2025 | |
Jupiter Endovascular
|
Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | Series B / Oct 07, 2025 | |
|
Jupiter Endovascular
|
Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | Series B / Oct 07, 2025 | |
|
Jupiter Endovascular
|
Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | Series B / Oct 07, 2025 | |
BRIUS
|
BRIUS is a healthcare company that focuses in the orthodontics and medical device industry. | $19.5M / Series B / May 06, 2025 | |
|
Jupiter Endovascular
|
Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | $21M / Series A / Aug 15, 2024 | |
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sonder Capital invest in?
Sonder Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Seed stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sonder Capital's check size?
Sonder Capital typically joins rounds of $8M–$18M at Seed, $13M–$22M at Series A and $20M–$70M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sonder Capital participates in.
How do I contact Sonder Capital?
Public channels for Sonder Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sonder Capital?
The team at Sonder Capital includes Andy McGibbon (Managing Partner), Jay Watkins (Managing Partner) and Colby Wood (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
